Literature DB >> 10934341

Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria.

S J Richards1, A C Rawstron, P Hillmen.   

Abstract

Within the contemporary multitude of complex methods used in clinical flow cytometry, very few techniques exist which can be described as disease-specific diagnostic tests. Detection of glycophosphatidylinositol (GPI)-linked antigens on hematopoietic cells using monoclonal antibodies and flow cytometry forms the basis of a specific diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). Absent or markedly diminished expression of GPI-linked antigens is, in the appropriate clinical setting, specific for all patients with PNH. Clinically, PNH is a syndrome characterized by bone marrow failure, acquired hemolytic anemia, and a thrombotic tendency. The molecular genetic lesion responsible for this condition is a somatic mutation of the X-linked pig-a gene within a multipotent hematopoietic stem cell. Due to its rarity, delay in diagnosis is not uncommon for patients with PNH. Once a definitive diagnosis is established, this can make a considerable impact on patient management and prognosis. In this article, we review the complimentary roles that molecular biology and flow cytometry have played in unraveling the genotypic and phenotypic aspects of this unique condition. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934341

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  20 in total

1.  Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations.

Authors:  Minoo Battiwalla; Mehmet Hepgur; Dalin Pan; Philip L McCarthy; Manmeet S Ahluwalia; Susan H Camacho; Petr Starostik; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2010-06-07       Impact factor: 3.058

Review 2.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

3.  A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America.

Authors:  Fan Yu; Yali Du; Bing Han
Journal:  Int J Hematol       Date:  2016-04-08       Impact factor: 2.490

4.  Morphological Spectrum of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-09       Impact factor: 0.900

Review 5.  Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.

Authors:  Lucio Luzzatto; Giacomo Gianfaldoni
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

6.  The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients.

Authors:  Neal S Young; Gabrielle Meyers; Hubert Schrezenmeier; Peter Hillmen; Anita Hill
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

7.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

8.  Sensitivity of the Pig-a assay for detecting gene mutation in rats exposed acutely to strong clastogens.

Authors:  Javed A Bhalli; Joseph G Shaddock; Mason G Pearce; Vasily N Dobrovolsky
Journal:  Mutagenesis       Date:  2013-05-15       Impact factor: 3.000

Review 9.  Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances.

Authors:  Prabhu Manivannan; Ankur Ahuja; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-08       Impact factor: 0.900

10.  Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report.

Authors:  E Mandala; C Lafaras; I Goulis; K Tsioni; V Georgopoulou; G Ilonidis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.